Fangzhou Jianke Expands into Chengdu, Showcasing H2H Digital Chronic Care Platform
Empowering Digital Healthcare with Technology, Innovating Chronic Disease Management Services. Recently, the opening ceremony of Fangzhou Jianke’s Southwest Branch (Chengdu) was held at Dongyuan Center in Chengdu, Sichuan Province. Xie Fangmin, Founder, Chairman, and CEO of Fangzhou Jianke, along with representatives from partner organizations including Gilead Sciences, Hong Kong Weijian Pharmaceutical Group, Jiangxi Qingfeng Pharmaceutical Co., Ltd., Zhejiang Otsuka Pharmaceutical Co., Ltd., Chengdu Yuanda Bio-Pharmaceutical Co., Ltd., Novartis, Sichuan Kelun Pharmaceutical Co., Ltd., Pfizer, Organon, Chengdu Better Pharmaceutical Co., Ltd., Chengdu Kanghong Pharmaceutical Group Co., Ltd., and Sichuan Mingxin Pharmaceutical, attended the event to witness this “Health Covenant” that gathers strength and collaboration.
Driven by factors such as the deepening aging population and rising public health awareness, China’s chronic disease management market is expanding rapidly. According to data from Frost & Sullivan, measured by gross merchandise value (GMV), the total size of China’s chronic disease management market grew swiftly from RMB 2,425.5 billion in 2015 to RMB 6,009.9 billion in 2021, and is projected to reach RMB 15,484.5 billion by 2030. Meanwhile, the Chinese government has repeatedly issued policies explicitly strengthening chronic disease management and supporting the development of internet healthcare, indicating significant growth potential for the chronic disease services market.
“Debuting” in Chengdu marks another significant milestone in the development of Fangzhou Jianke, while also opening a “new window” for communication among partners. Xie Fangmin stated, “We look forward to more partners and healthcare professionals joining the Fangzhou Jianke H2H service platform to collaborate on innovation and write a new chapter in chronic disease management services.”
At the opening ceremony, Xie Fangmin stated in his address that the southwestern region boasts a robust environment for the development of pharmaceutical enterprises. Following the commencement of operations by Fangzhou Jianke’s Southwest branch, the company will uphold an open and collaborative approach. It aims to enable partners to transcend geographical limitations through Fangzhou Jianke’s chronic disease management platform, thereby facilitating the expansion of their businesses across China.
The internet healthcare sector is building momentum and unleashing new growth drivers. For traditional pharmaceutical companies, survival demands transformation, which means identifying entirely new sources of business growth. For partners, Fangzhou Jianke’s entry into the Chengdu market will undoubtedly bring more growth opportunities to the industry ecosystem.
Effective out-of-hospital management represents a new trend in chronic disease services. Shang Jun, Regional Medical Manager (RMM) for Gilead’s HIV division in Western China, stated that the establishment of Fangzhou Jianke’s Southwest branch marks a new starting point. He expressed anticipation for deeper business collaboration between the two parties in the western region, leveraging Fangzhou Jianke’s technological and supply chain advantages to benefit more patients in western China and foster a win-win scenario for the government, hospitals, and patients.
Discussing the outlook for collaboration with Fangzhou Jianke, Li Zhengchun, Director of Kelun Pharmaceutical’s Large Retail Business Division, stated, “The health industry in China is currently entering an accelerated growth phase. As a local enterprise based in Sichuan Province, we possess strong resources. We hope that the establishment of our Southwest company will inject new momentum into traditional pharmaceutical enterprises.” He expressed his expectation that Kelun and Fangzhou Jianke would deepen their cooperation and resource sharing in pharmaceutical warehousing and medical trade, joining forces to strengthen and expand the internet healthcare industry.
Not only does Fangzhou Jianke actively provide partners with new channels for business expansion, but it also leverages its all-media matrix and platforms such as the Jianke Doctor APP to offer a range of customized content and digital services, including public welfare science popularization lectures and search engine optimization. Through these digital channels, Fangzhou Jianke precisely delivers accurate health education information to patients with chronic diseases, thereby enhancing the social value of its partners across multiple dimensions.
Regarding the outlook for innovative digital services, representatives from Weijian Pharmaceutical, Qingfeng Pharmaceutical, Otsuka Pharmaceutical, Yuandong Biology, and Novartis jointly stated that the development of the health industry cannot thrive without the infusion of “fresh blood.” They expressed their eagerness to strengthen collaboration with Fangzhou Jianke in areas such as pharmaceutical innovation and public welfare health education, working together to create superior cooperative projects and explore endless possibilities.
In response to the national call and with a commitment to innovating digital services for chronic disease management, Fangzhou Jianke has established an H2H (Hospital-to-Home) smart healthcare ecosystem, upholding its mission of “Making Everyone Healthier.” In February 2023, Fangzhou Jianke’s H2H Smart Ecosystem Health Platform was selected as one of Guangzhou’s Typical Application Scenarios for the Digital Economy in 2022. In March, Guangzhou Fangzhou Information Technology Co., Ltd., a subsidiary of Fangzhou Jianke, was recognized as a High-Tech Enterprise for 2022, owing to its strengths in core independent intellectual property rights, technological achievement transformation capabilities, and organizational management levels in research and development.
As a key liaison for communication and coordination with local partners, the opening of Ark Health’s Southwest branch marks the formal establishment of its nationwide business development framework, centered in Beijing, Shanghai, Guangzhou, and Chengdu. Moving forward, Ark Health will collaborate with local partners to explore innovative models for the pharmaceutical supply chain. Through Ark Health’s chronic disease management platform, partners can access the national market and achieve greater social impact.
Go All Out to Promote Development and Strive for a Strong Start! In the internet sector, where prospects and opportunities coexist, Fangzhou Jianke is firmly confident in continuing to seek industry breakthroughs. By collaborating with industry partners to build and share resources, we aim to drive the chronic disease service ecosystem toward positive and robust growth, ushering in a more brilliant “Healthy Future.”